NCT03205306

Brief Summary

The purpose of the study is to systematically capture and characterize mental comorbidities for patients with myasthenia gravis. Anxiety disorders and depression for example, can negatively affect the quality of life and lead to e.g. unemployment and early retirement especially in young patients. Additionally the researchers want to find out in what way certain aspects of the disease have an influence on the quality of life, and whether different concepts of coping with the disease have different effects on the quality of life for patients with myasthenia gravis. During the study, close relatives of patients will also be asked to provide input about their current stress situation in the context of supporting their relative. Based on the results, the investigators want to improve and supplement established treatment concepts, to ensure a more comprehensive and individual treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,399

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 8, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 8, 2017

Completed
24 days until next milestone

First Posted

Study publicly available on registry

July 2, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 14, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 14, 2017

Completed
Last Updated

January 10, 2023

Status Verified

January 1, 2023

Enrollment Period

7 months

First QC Date

June 8, 2017

Last Update Submit

January 6, 2023

Conditions

Keywords

Myasthenia GravisPsycheDepressionAnxiety DisorderPosttraumatic Stress DisorderDisease Processing

Outcome Measures

Primary Outcomes (1)

  • Questionnaire Survey (Patient)

    * Questionnaire for self-completion by patients containing questions about general information, information on myasthenia, information on diagnosis of mental illness and psychotherapeutic care * Hospital Anxiety and Depression Scale (HADS - questionnaire for self-completion by patients to determine the levels of anxiety and depression) * Breslau scale PTBS-7 (questionnaire for self-completion by patients to determine the levels of Probability of posttraumatic stress disorder (PTSD)) * Mya Quality of Life 15 (Mya QoL15 - questionnaire for self-completion by patients for use as a measure of health outcome) * Freiburg questionnaire for coping (FKV - questionnaire is used to assess disease processing modes at the levels of cognition, emotion, and behavior)

    directly after inclusion in the study

Secondary Outcomes (1)

  • "Häusliche Pflegeskala" (HPS)

    directly after inclusion in the study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Myasthenia Gravis and their relatives

You may qualify if:

  • Patients with Myasthenia Gravis
  • Age ≥18 years

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NeuroCure Clinical Research Center (NCRC), Charité

Berlin, 10117, Germany

Location

Related Publications (1)

  • Marbin D, Piper SK, Lehnerer S, Harms U, Meisel A. Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep. 2022 Nov 11;12(1):19275. doi: 10.1038/s41598-022-22078-3.

MeSH Terms

Conditions

Myasthenia GravisDepressionAnxiety DisordersStress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Paraneoplastic Syndromes, Nervous SystemNervous System NeoplasmsNeoplasms by SiteNeoplasmsParaneoplastic SyndromesAutoimmune Diseases of the Nervous SystemNervous System DiseasesNeurodegenerative DiseasesNeuromuscular Junction DiseasesNeuromuscular DiseasesAutoimmune DiseasesImmune System DiseasesBehavioral SymptomsBehaviorMental DisordersStress Disorders, TraumaticTrauma and Stressor Related Disorders

Study Officials

  • Andreas Meisel, Prof. Dr. med.

    Charite University, Berlin, Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med.

Study Record Dates

First Submitted

June 8, 2017

First Posted

July 2, 2017

Study Start

May 8, 2017

Primary Completion

December 14, 2017

Study Completion

December 14, 2017

Last Updated

January 10, 2023

Record last verified: 2023-01

Locations